Sickle cell disease: A global call to action

FHS
July 12, 2023
4:44 am

Reducing the burden of Sickle Cell Disease (SCD) requires substantial financial and political commitment to improving data-collection, diagnosis, treatment and training – doing so will positively impact the lives of millions of patients and families worldwide – says a new Commission published in The Lancet Haematology journal.

FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu

Share this article In the DESTINY-PanTumor02 trial, subjects treated with Daiichi Sankyo-AstraZeneca’s Enhertu achieved a confirmed ORR of 51.4%. Credit: Anna in Sweden / Shutterstock.com.

April 8, 2024

Molecular glues are the latest craze in pharma research, but what are they? – Pharmaceutical Technology

Share this article Lenalidomide is a prominent molecular glue currently on the market. Image: Irina Anosova/Shutterstock. February’s announcement that Novo Nordisk was partnering with a

March 21, 2024

With few specifics, Recursion underwhelms with first Phase 2 readout, but ‘plans to advance’ drug

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.